

VESicare (solifenacin succinate) Tablets Clinical Update

Clinical Update: FDA Approves VESicare LS (solifenacin succinate) Oral Suspension for Neurogenic Detrusor Overactivity (NDO) Pediatric Patients
FDA approval date: May 26, 2020

VESicare LS™ (solifenacin succinate) is a prescription medicine for children 2 years of age and older with a condition called neurogenic detrusor overactivity. It is used to increase the amount of urine your bladder can hold and reduce urine leakage. Patients with NDO may experience involuntary bladder contractions, which can lead to symptoms of urinary urgency, frequency and incontinence. Spina bifida, a congenital spinal cord defect, is a common cause of NDO in children. VESicare LS is not for everyone. Do not take VESicare LS if you have delayed or slow emptying of your stomach (gastric retention), have an eye problem called "uncontrolled narrow-angle glaucoma, or are allergic to solifenacin succinate or any of the ingredients in VESicare LS.

The U.S. Food and Drug Administration (FDA) has approved VESicare LS (solifenacin succinate) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 2 years and older. VESicare LS is an oral suspension dosage form that was specifically developed to facilitate dosing and administration in the pediatric population. VESicare (solifenacin succinate) tablets were initially approved in the United States in 2004. VESicare LS oral suspension will come in a 5 mg/5 mL (1 mg/mL) oral suspension. It is also available in Europe.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.